Drug-drug interactions of triazole antifungal agents in multimorbid patients and implications for patient care

Current Drug Metabolism

Volumn 10, Issue 4, 2009, Pages 395-409

  Nivoix, Yasmine ^a,b   Ubeaud Sequier, Geneviève ^a,b   Engel, Pauline ^b   Levêque, Dominique ^a   Herbrecht, Raoul ^a  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Drug interactions; Fluconazole; Itraconazole; Posaconazole; Voriconazole

Indexed keywords

ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ATAZANAVIR; BENZODIAZEPINE DERIVATIVE; BUSULFAN; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN; EFAVIRENZ; FLUCONAZOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; METHYLPREDNISOLONE; NARCOTIC ANALGESIC AGENT; PLACEBO; POSACONAZOLE; PREDNISOLONE; RAPAMYCIN; RIFABUTIN; RIFAMPICIN; RITONAVIR; SAQUINAVIR; TACROLIMUS; TRIAZOLE; UNINDEXED DRUG; VINCRISTINE; VORICONAZOLE; ZIDOVUDINE;

AIDS RELATED COMPLEX; ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; BIOTRANSFORMATION; CRYPTOCOCCAL MENINGITIS; DRUG CLEARANCE; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAXIMUM PLASMA CONCENTRATION; MYCOSIS; NEOPLASM; PATIENT CARE; PATIENT EDUCATION; PROPHYLAXIS; REVIEW; STOMACH PH; SYSTEMIC THERAPY;

ANTIFUNGAL AGENTS; BIOTRANSFORMATION; COMORBIDITY; DRUG INTERACTIONS; FOOD; GASTRIC ACID; GUIDELINES AS TOPIC; HUMANS; MEMBRANE TRANSPORT PROTEINS; MYCOSES; RISK FACTORS; TRIAZOLES;

EID: 68349136859     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920009788499012     Document Type: Review

References (172)

1. Lim, S.G.; Sawyerr, A.M.; Hudson, M.; Sercombe, J.; Pounder, R.E. Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity. Aliment. Pharmacol. Ther., 1993, 7(3), 317-321.
2. Debruyne, D. Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses. Clin. Pharmacokinet., 1997, 33(1), 52-77.
3. VFEND®, I.V. (voriconazole) for injection, VFEND® tablets (voriconazole), VFEND® (voriconazole) for oral suspension [prescribing information]. New York, NY: Pfizer Inc; March 2008.
4. Johnson, M.D.; Hamilton, C.D.; Drew, R.H.; Sanders, L.L.; Pennick, G.J.; Perfect, J.R. A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution. J. Antimicrob. Chemother., 2003, 51(2), 453-457.
5. Jaruratanasirikul, S.; Kleepkaew, A. Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole. Eur. J. Clin. Pharmacol., 1997, 52(3), 235-237.
6. Lange, D.; Pavao, J.H.; Wu, J.; Klausner, M. Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers. J. Clin. Pharmacol., 1997, 37(6), 535-540.
7. Krishna, G.; Moton, A.; Ma, L.; Medlock, M.M.; McLeod, J. The pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob. Agents. Chemother., 2009, 53(3), 958-966.
8. Zimmermann, T.; Yeates, R.A.; Laufen, H.; Pfaff, G.; Wildfeuer, A. Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Eur. J. Clin. Pharmacol., 1994, 46(2), 147-150.
9. Sporanox® (itraconazole) capsules [prescribing information]. Titusville, NJ: Janssen; June 2006.
10. Barone, J.A.; Moskovitz, B.L.; Guarnieri, J.; Hassell, A.E.; Colaizzi, J.L.; Bierman, R.H.; Jessen, L. Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. Pharmacotherapy, 1998, 18(2), 295-301.
11. Courtney, R.; Wexler, D.; Radwanski, E.; Lim, J.; Laughlin, M. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br. J. Clin. Pharmacol., 2003, 57(2), 218-222.
12. Wang, E.J.; Lew, K.; Casciano, C.N.; Clement, R.P.; Johnson, W.W. Interaction of common azole antifungals with P glycoprotein. Antimicrob. Agents Chemother., 2002, 46(1), 160-165.
13. Gupta, A.; Unadkat, J.D.; Mao, Q. Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP). J. Pharm. Sci., 2007, 96(12), 3226-3235.
14. Niwa, T.; Shiraga, T.; Takagi, A. Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol. Pharm. Bull., 2005, 28(9), 1805-1808.
15. Sakaeda, T.; Iwaki, K.; Kakumoto, M.; Nishikawa, M.; Niwa, T.; Jin, J.S.; Nakamura, T.; Nishiguchi, K.; Okamura, N.; Okumura, K. Effect of micafungin on cytochrome p450 3a4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs. J. Pharm. Pharmacol., 2005, 57(6), 759-764.
16. Wacher, V.J.; Wu, C.Y.; Benet, L.Z. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog., 1995, 13(3), 129-134.
17. Hyland, R.; Jones, B.C.; Smith, D.A. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug. Metab. Dispos., 2003, 31(5), 540-547.
18. Ikeda, Y.; Umemura, K.; Kondo, K.; Sekiguchi, K.; Miyoshi, S.; Nakashima, M. Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status. Clin. Pharmacol. Ther., 2004, 75(6), 587-588.
19. Wexler, D.; Courtney, R.; Richards, W.; Banfield, C.; Lim, J.; Laughlin, M. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur. J. Pharm. Sci., 2004, 21(5), 645-653.
20. Saad, A.H.; DePestel, D.D.; Carver, P.L. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy, 2006, 26(12), 1730-1744.
21. Guengerich, F.P. Role of cytochrome P450 enzymes in drug-drug interactions. Adv. Pharmacol., 1997, 43, 7-35.
22. Flockhart, D.A. Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19. Clin. Pharmacokinet., 1995, 29 (Suppl 1), 45-52.
23. Lin, J.H. Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. Adv. Drug Deliv. Rev., 2003, 55(1), 53-81.
24. Debruyne, D.; Ryckelynck, J.P. Clinical pharmacokinetics of fluconazole. Clin. Pharmacokinet., 1993, 24(1), 10-27.
25. Venkatakrishnan, K.; Von Moltke, L.L.; Greenblatt, D.J. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin. Pharmacokinet., 2000, 38(2), 111-180.
26. Heykants, J.; Van Peer, A.; Van de Velde, V.; Van Rooy, P.; Meuldermans, W.; Lavrijsen, K.; Woestenborghs, R.; Van Cutsem, J.; Cauwenbergh, G. The clinical pharmacokinetics of itraconazole: an overview. Mycoses, 1989, 32, 67-87.
27. Hulsewede, J.W.; Dermoumi, H.; Ansorg, R. Determination of itraconazole and hydroxy-itraconazole in sera using high-performance-liquid-chromatography and a bioassay. Zentralbl. Bakteriol., 1995, 282(4), 457-464.
28. Purkins, L.; Wood, N.; Kleinermans, D.; Nichols, D. Voriconazole does not affect the steady-state pharmacokinetics of digoxin. Br. J. Clin. Pharmacol., 2003, 56, 45-50.
29. Ghosal, A.; Hapangama, N.; Yuan, Y.; Achanfuo-Yeboah, J.; Iannucci, R.; Chowdhury, S.; Alton, K.; Patrick, J.E.; Zbaida, S. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil). Drug Metab. Dispos., 2004, 32(2), 267-271.
30. Krieter, P.; Flannery, B.; Musick, T.; Gohdes, M.; Martinho, M.; Courtney, R. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob. Agents Chemother., 2004, 48(9), 3543-3551.
31. Mahfouz, T.; Anaissie, E. Prevention of fungal infections in the immunocompromised host. Curr. Opin. Investig. Drugs, 2003, 4(8), 974-990.
32. Segal, B.H.; Herbrecht, R.; Stevens, D.A.; Ostrosky-Zeichner, L.; Sobel, J.; Viscoli, C.; Walsh, T.J.; Maertens, J.; Patterson, T.F.; Perfect, J.R.; Dupont, B.; Wingard, J.R.; Calandra, T.; Kauffman, C.A.; Graybill, J.R.; Baden, L.R.; Pappas, P.G.; Bennett, J.E.; Kontoyiannis, D.P.; Cordonnier, C.; Viviani, M.A.; Bille, J.; Almyroudis, N.G.; Wheat, L.J.; Graninger, W.; Bow, E.J.; Holland, S.M.; Kullberg, B.J.; Dismukes, W.E.; De Pauw, B.E. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria. Clin. Infect. Dis., 2008, 47, 674-683.
33. Marr, K.A.; Carter, R.A.; Boeckh, M.; Martin, P.; Corey, L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood, 2002, 100(13), 4358-4366.
34. Marr, K.A.; Leisenring, W.; Crippa, F.; Slattery, J.T.; Corey, L.; Boeckh, M.; McDonald, G.B. Cyclophosphamide metabolism is affected by azole antifungals. Blood, 2004, 103(4), 1557-1559.
35. Buggia, I.; Zecca, M.; Alessandrino, E.P.; Locatelli, F.; Rosti, G.; Bosi, A.; Pession, A.; Rotoli, B.; Majolino, I.; Dallorso, A.; Regazzi, M.B. Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (Gruppo Italiano Trapianto di Midollo Osseo). Anticancer Res., 1996, 16(4A), 2083-2088.
36. Kamaluddin, M.; McNally, P.; Breatnach, F.; O'Marcaigh, A.; Webb, D.; O'Dell, E.; Scanlon, P.; Butler, K.; O'Meara, A. Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies. Acta Paediatr., 2001, 90(10), 1204-1207.
37. NOXAFIL® (posaconazole) oral suspension [prescribing information]. Kenilworth, NJ: Schering Corporation; May 2008.
38. Varis, T.; Kivisto, K.T.; Backman, J.T.; Neuvonen, P.J. Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers. Pharmacol. Toxicol., 1999, 85(1), 29-32.
39. Lebrun-Vignes, B.; Archer, V.C.; Diquet, B.; Levron, J.C.; Chosidow, O.; Puech, A.J.; Warot, D. Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. Br. J. Clin. Pharmacol., 2001, 51(5), 443-450.
40. Assan, R.; Fredj, G.; Larger, E.; Feutren, G.; Bismuth, H. FK 506/ fluconazole interaction enhances FK 506 nephrotoxicity. Diabète Métab., 1994, 20(1), 49-52.
41. Sugar, A.M.; Saunders, C.; Idelson, B.A.; Bernard, D.B. Interaction of fluconazole and cyclosporine. Ann. Intern. Med., 1989, 110(10), 844.
42. Torregrosa, V.; de la, T.M.; Campistol, J.M.; Oppenheimer, F.; Ricart, M.J.; Vilardell, J.; Andreu, J. Interaction of fluconazole with ciclosporin, A. Nephron., 1992, 60(1), 125-126.
43. Sud, K.; Singh, B.; Krishna, V.S.; Thennarasu, K.; Kohli, H.S.; Jha, V.; Gupta, K.L.; Sakhuja, V. Unpredictable cyclosporin - fluconazole interaction in renal transplant recipients. Nephrol. Dial. Transplant., 1999, 14(7), 1698-1703.
44. Toda, F.; Tanabe, K.; Ito, S.; Shinmura, H.; Tokumoto, T.; Ishida, H.; Toma, H. Tacrolimus trough level adjustment after administration of fluconazole to kidney recipients. Transplant. Proc., 2002, 34(5), 1733-1735.
45. Manez, R.; Martin, M.; Raman, D.; Silverman, D.; Jain, A.; Warty, V.; Gonzalez-Pinto, I.; Kusne, S.; Starzl, T.E. Fluconazole therapy in transplant recipients receiving FK506. Transplantation, 1994, 57(10), 1521-1523.
46. Mahnke, C.B.; Sutton, R.M.; Venkataramanan, R.; Michaels, M.; Kurland, G.; Boyle, G.J.; Law, Y.M.; Miller, S.A.; Pigula, F.A.; Gandhi, S.; Webber, S.A. Tacrolimus dosage requirements after initiation of azole antifungal therapy in pediatric thoracic organ transplantation. Pediatr. Transplant., 2003, 7(6), 474-478.
47. Hairhara, Y.; Makuuchi, M.; Kawarasaki, H.; Takayama, T.; Kubota, K.; Ito, M.; Tanaka, H.; Yoshino, H.; Hirata, M.; Kita, Y.; Kusaka, K.; Sano, K.; Saiura, A.; Ijichi, M.; Matsukura, A.; Watanabe, M.; Hashizume, K.; Nakatsuka, T. Effect of fluconazole on blood levels of tacrolimus. Transplant. Proc., 1999, 31(7), 2767.
48. Osowski, C.L.; Dix, S.P.; Lin, L.S.; Mullins, R.E.; Geller, R.B.; Wingard, J.R. Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. Transplantation, 1996, 61(8), 1268-1272.
49. Cervelli, M.J. Fluconazole-sirolimus drug interaction [letter]. Transplantation, 2002, 74(10), 1477-1478.
50. Sadaba, B.; Campanero, M.A.; Quetglas, E.G.; Azanza, J.R. Clinical relevance of sirolimus drug interactions in transplant patients. Transplant. Proc., 2004, 36(10), 3226-3228.
51. Back, D.J.; Tjia, J.F. Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br. J. Clin. Pharmacol., 1991, 32(5), 624-626.
52. Kramer, M.R.; Marshall, S.E.; Denning, D.W.; Keogh, A.M.; Tucker, R.M.; Galgiani, J.N.; Lewiston, N.J.; Stevens, D.A.; Theodore, J. Cyclosporine and itraconazole interaction in heart and lung transplant recipients. Ann. Intern. Med., 1990, 113(4), 327-329.
53. Florea, N.R.; Capitano, B.; Nightingale, C.H.; Hull, D.; Leitz, G.J.; Nicolau, D.P. Beneficial pharmacokinetic interaction between cyclosporine and itraconazole in renal transplant recipients. Transplant. Proc., 2003, 35(8), 2873-2877.
54. Irani, S.; Fattinger, K.; Schmid-Mahler, C.; Achermann, E.; Speich, R.; Boehler, A. Blood concentration curve of cyclosporine: impact of itraconazole in lung transplant recipients. Transplantation, 2007, 83(8), 1130-1133.
55. Furlan, V.; Parquin, F.; Penaud, J.F.; Cerrina, J.; Ladurie, F.L.; Dartevelle, P.; Taburet, A.M. Interaction between tacrolimus and itraconazole in a heart-lung transplant recipient. Transplant. Proc., 1998, 30(1), 187-188.
56. Capone, D.; Gentile, A.; Imperatore, P.; Palmiero, G.; Basile, V. Effects of itraconazole on tacrolimus blood concentrations in a renal transplant recipient. Ann. Pharmacother., 1999, 33(10), 1124-1125.
57. Outeda Macias, M.; Salvador, P.; Hurtado, J.L.; Martin, I. Tacrolimus-itraconazole interaction in a kidney transplant patient. Ann. Pharmacother., 2000, 34(4), 536.
58. Cervelli, M.J.; Russ, G.R. Itraconazole-tacrolimus drug interaction. Ther. Drug. Monit., 2003, 25(4), 483-484.
59. Banerjee, R.; Leaver, N.; Lyster, H.; Banner, N.R. Coadministration of itraconazole and tacrolimus after thoracic organ transplantation. Transplant. Proc., 2001, 33(1-2), 1600-1602.
60. Kramer, M.R.; Merin, G.; Rudis, E.; Bar, I.; Nesher, T.; Bublil, M.; Milgalter, E. Dose adjustment and cost of itraconazole prophylaxis in lung transplant recipients receiving cyclosporine and tacrolimus (FK 506). Transplant. Proc., 1997, 29(6), 2657-2659.
61. Shitrit, D.; Ollech, J.E.; Ollech, A.; Bakal, I.; Saute, M.; Sahar, G.; Kramer, M.R. Itraconazole prophylaxis in lung transplant recipients receiving tacrolimus (FK 506): efficacy and drug interaction. J. Heart Lung Transplant., 2005, 24(12), 2148-2152.
62. Romero, A.J.; Pogamp, P.L.; Nilsson, L.G.; Wood, N. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin. Pharmacol. Ther., 2002, 71(4), 226-234.
63. Groll, A.H.; Kolve, H.; Ehlert, K.; Paulussen, M.; Vormoor, J. Pharmacokinetic interaction between voriconazole and ciclosporin A following allogeneic bone marrow transplantation. J. Antimicrob. Chemother., 2004, 53(1), 113-114.
64. Kuypers, D.R.; Claes, K.; Evenepoel, P.; Vanrenterghem, Y. Clinically relevant drug interaction between voriconazole and tacrolimus in a primary renal allograft recipient. Transplantation, 2006, 81(12), 1750-1752.
65. Tintillier, M.; Kirch, L.; Goffin, E.; Cuvelier, C.; Pochet, J.M. Interaction between voriconazole and tacrolimus in a kidney-transplanted patient. Nephrol. Dial. Transplant., 2005., 20(3), 664-665.
66. Mathis, A.S.; Shah, N.K.; Friedman, G.S. Combined use of sirolimus and voriconazole in renal transplantation: a report of two cases. Transplant. Proc., 2004, 36(9), 2708-2709.
67. Venkataramanan, R.; Zang, S.; Gayowski, T.; Singh, N. Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes. Antimicrob. Agents Chemother., 2002, 46(9), 3091-3093.
68. Marty, F.M.; Lowry, C.M.; Cutler, C.S.; Campbell, B.J.; Fiumara, K.; Baden, L.R.; Antin, J.H. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant., 2006, 12(5), 552-559.
69. Sansone-Parsons, A.; Krishna, G.; Martinho, M.; Kantesaria, B.; Gelone, S.; Mant, T.G. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy, 2007, 27(6), 825-834.
70. Moton, A.; Ma, L.; Krishna, G.; Martinho, M.; Seiberling, M.; McLeod, J. Effect of oral posaconazole (POS) on the pharmacokinetics (PK) of sirolimus. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2007; Chicago, IL.
71. Diflucan® (fluconazole tablets)(fluconazole injection - for intravenous infusion only)(fluconazole for oral suspension) [prescribing information]. New York, NY: Pfizer Inc; August 2004.
72. Sahai, J.; Gallicano, K.; Pakuts, A.; Cameron, D.W. Effect of fluconazole on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus. J. Infect. Dis., 1994, 169(5), 1103-1107.
73. Koks, C.H.; Crommentuyn, K.M.; Hoetelmans, R.M.; Burger, D.M.; Koopmans, P.P.; Mathot, R.A.; Mulder, J.W.; Meenhorst, P.L.; Beijnen, J.H. The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals. Br. J. Clin. Pharmacol., 2001, 51(6), 631-635.
74. Jaruratanasirikul, S.; Sriwiriyajan, S. Pharmacokinetic study of the interaction between itraconazole and nevirapine. Eur. J. Clin. Pharmacol., 2007, 63(5), 451-456.
75. Koo, H.L.; Hamill, R.J.; Andrade, R.A. Drug-drug interaction between itraconazole and efavirenz in a patient with AIDS and disseminated histoplasmosis. Clin. Infect. Dis., 2007, 45(6), e77-e79.
76. Liu, P.; Foster, G.; Labadie, R.R.; Gutierrez, M.J.; Sharma, A. Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects. J. Clin. Pharmacol., 2008, 48(1), 73-84.
77. Liu, P.; Foster, G.; Gandelman, K.; Labadie, R.R.; Allison, M.J.; Gutierrez, M.J.; Sharma, A. Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects. Antimicrob. Agents Chemother., 2007, 51(10), 3617-3626.
78. Krishna, G.; Moton, A.; Ma, L.; Martinho M, Seiberling M, McLeod, J. Effect of oral posaconazole on pharmacokinetics of atazanavir alone and with ritonavir: results of an open-label crossover study. Presented at: 13th Congress of the European Association of Hospital Pharmacists; February 27-29, 2008; Maastricht, Netherlands.
79. Moton A, Ma L, Krishna G, Martinho M, Seiberling M, McLeod, J. Pharmacokinetics of the antifungal posaconazole and the nonnucleoside reverse transcriptase inhibitor efavirenz when coadministered in healthy adult volunteers. Presented at: 13th Congress of the European Association of Hospital Pharmacists; February 27-29., 2008; Maastricht, Netherlands.
80. Sampol, E.; Lacarelle, B.; Rajaonarison, J.F.; Catalin, J.; Durand, A. Comparative effects of antifungal agents on zidovudine glucuronidation by human liver microsomes. Br. J. Clin. Pharmacol., 1995, 40(1), 83-86.
81. Asgari, M.; Back, D.J. Effect of azoles on the glucuronidation of zidovudine by human liver UDP-glucuronosyltransferase. J. Infect. Dis., 1995, 172(6), 1634-1636.
82. Trapnell, C.B.; Klecker, R.W.; Jamis-Dow, C.; Collins, J.M. Glucuronidation of 3′-azido-3′-deoxythymidine (zidovudine) by human liver microsomes: relevance to clinical pharmacokinetic interactions with atovaquone, fluconazole, methadone, and valproic acid. Antimicrob. Agents Chemother., 1998, 42(7), 1592-1596.
83. Uchaipichat, V.; Winner, L.K.; Mackenzie, P.I.; Elliot, D.J.; Williams, J.A.; Miners, J.O. Quantitative prediction of in. vivo inhibitory interactions involving glucuronidated drugs from in. vitro data: the effect of fluconazole on zidovudine glucuronidation. Br. J. Clin. Pharmacol., 2006, 61(4), 427-439.
84. Brockmeyer, N.H.; Tillmann, I.; Mertins, L.; Barthel, B.; Goos, M. Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients. Eur. J. Med. Res., 1997, 2(9), 377-383.
85. Crommentuyn, K.M.; Mulder, J.W.; Sparidans, R.W.; Huitema, A.D.; Schellens, J.H.; Beijnen, J.H. Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis. Clin. Infect. Dis., 2004, 38(8), e73-e75.
86. Purkins, L.; Wood, N.; Kleinermans, D.; Love, E.R. No clinically significant pharmacokinetic interactions between voriconazole and indinavir in healthy volunteers. Br. J. Clin. Pharmacol., 2003, 56, 62-68.
87. Kanda, Y.; Kami, M.; Matsuyama, T.; Mitani, K.; Chiba, S.; Yazaki, Y.; Hirai, H. Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole. Hematol. Oncol., 1998, 16(1), 33-37.
88. Panomvana Na Ayudhya, D.; Thanompuangseree, N.; Tansuphaswadikul, S. Effect of rifampicin on the pharmacokinetics of fluconazole in patients with AIDS. Clin. Pharmacokinet., 2004, 43(11), 725-732.
89. Trapnell, C.B.; Narang, P.K.; Li, R.; Lavelle, J.P. Increased plasma rifabutin levels with concomitant fluconazole therapy in HIV-infected patients. Ann. Intern. Med., 1996, 124(6), 573-576.
90. Krishna, G.; Parsons, A.; Kantesaria, B.; Mant, T. Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men. Curr. Med. Res. Opin., 2007, 23(3), 545-552.
91. Olkkola, K.T.; Ahonen, J.; Neuvonen, P.J. The effect of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth. Analg., 1996, 82(3), 511-516.
92. Ahonen, J.; Olkkola, K.T.; Neuvonen, P.J. Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam. Eur. J. Clin. Pharmacol., 1997, 51(5), 415-419.
93. Olkkola, K.T.; Backman, J.T.; Neuvonen, P.J. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin. Pharmacol. Ther., 1994, 55(5), 481-485.
94. Ahonen, J.; Olkkola, K.T.; Neuvonen, P.J. Lack of effect of antimycotic itraconazole on the pharmacokinetics or pharmacodynamics of temazepam. Ther. Drug Monit., 1996, 18(2), 124-127.
95. Ahonen, J.; Olkkola, K.T.; Neuvonen, P.J. The effect of the antimycotic itraconazole on the pharmacokinetics and pharmacodynamics of diazepam. Fundam. Clin. Pharmacol., 1996, 10(3), 314-318.
96. Saari, T.I.; Laine, K.; Leino, K.; Valtonen, M.; Neuvonen, P.J.; Olkkola, K.T. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Clin. Pharmacol. Ther., 2006, 79(4), 362-370.
97. Liu, P.; Foster, G.; Labadie, R.; Somoza, E.; Sharma, A. Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy. Antimicrob. Agents Chemother., 2007, 51(1), 110-118.
98. Cobb, M.N.; Desai, J.; Brown, L.S., Jr.; Zannikos, P.N.; Rainey, P.M. The effect of fluconazole on the clinical pharmacokinetics of methadone. Clin. Pharmacol. Ther., 1998, 63(6), 655-662.
99. Saari, T.I.; Laine, K.; Neuvonen, M.; Neuvonen, P.J.; Olkkola, K.T. Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl. Eur. J. Clin. Pharmacol., 2008, 64(1), 25-30.
100. Blum, R.A.; Wilton, J.H.; Hilligoss, D.M.; Gardner, M.J.; Henry, E.B.; Harrison, N.J.; Schentag, J.J. Effect of fluconazole on the disposition of phenytoin. Clin. Pharmacol. Ther., 1991, 49(4), 420-425.
101. Finch, C.K.; Green, C.A.; Self, T.H. Fluconazole-carbamazepine interaction. South. Med. J., 2002, 95(9), 1099-1100.
102. Nair, D.R.; Morris, H.H. Potential fluconazole-induced carbamazepine toxicity. Ann. Pharmacother, 1999, 33(7-8), 790-792.
103. Ulivelli, M.; Rubegni, P.; Nuti, D.; Bartalini, S.; Giannini, F.; Rossi, S. Clinical evidence of fluconazole-induced carbamazepine toxicity. J. Neurol., 2004, 251(5), 622-623.
104. Ducharme, M.P.; Slaughter, R.L.; Warbasse, L.H.; Chandrasekar, P.H.; Van, d.V., V; Mannens, G.; Edwards, D.J. Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. Clin. Pharmacol. Ther., 1995, 58(6), 617-624.
105. Purkins, L.; Wood, N.; Ghahramani, P.; Love, E.R.; Eve, M.D.; Fielding, A. Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration. Br. J. Clin. Pharmacol., 2003, 56, 37-44.
106. Crussell-Porter, L.L.; Rindone, J.P.; Ford, M.A.; Jaskar, D.W. Low-dose fluconazole therapy potentiates the hypoprothrombinemic response of warfarin sodium. Arch. Intern. Med., 1993, 153(1), 102-104.
107. Gericke, K.R. Possible interaction between warfarin and fluconazole. Pharmacotherapy, 1993, 13(5), 508-509.
108. Purkins, L.; Wood, N.; Kleinermans, D.; Nichols, D. Voriconazole potentiates warfarin-induced prothrombin time prolongation. Br. J. Clin. Pharmacol., 2003, 56, 24-29.
109. Shaukat, A.; Benekli, M.; Vladutiu, G.D.; Slack, J.L.; Wetzler, M.; Baer, M.R. Simvastatin-fluconazole causing rhabdomyolysis. Ann. Pharmacother., 2003, 37(7-8), 1032-1035.
110. Moro, H.; Tsukada, H.; Tanuma, A.; Shirasaki, A.; Iino, N.; Nishibori, T.; Nishi, S.; Gejyo, F. Rhabdomyolysis after simvastatin therapy in an HIV-infected patient with chronic renal failure. Aids Patient Care STDS, 2004, 18(12), 687-690.
111. Kahri, J.; Valkonen, M.; Backlund, T.; Vuoristo, M.; Kivisto, K.T. Rhabdomyolysis in a patient receiving atorvastatin and fluconazole. Eur. J. Clin. Pharmacol., 2005, 60(12), 905-907.
112. Kantola, T.; Backman, J.T.; Niemi, M.; Kivisto, K.T.; Neuvonen, P.J. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur. J. Clin. Pharmacol., 2000, 56(3), 225-229.
113. Kivisto, K.T.; Kantola, T.; Neuvonen, P.J. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br. J. Clin. Pharmacol., 1998, 46(1), 49-53.
114. Neuvonen, P.J.; Kantola, T.; Kivisto, K.T. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin. Pharmacol. Ther., 1998, 63(3), 332-341.
115. Mazzu, A.L.; Lasseter, K.C.; Shamblen, E.C.; Agarwal, V.; Lettieri, J.; Sundaresen, P. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clin. Pharmacol. Ther., 2000, 68(4), 391-400.
116. Kantola, T.; Kivisto, K.T.; Neuvonen, P.J. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin. Pharmacol. Ther., 1998, 64(1), 58-65.
117. Kang, B.C.; Yang, C.Q.; Cho, H.K.; Suh, O.K.; Shin, W.G. Influence of fluconazole on the pharmacokinetics of omeprazole in healthy volunteers. Biopharm. Drug. Dispos., 2002, 23(2), 77-81.
118. Jaruratanasirikul, S.; Sriwiriyajan, S. Effect of omeprazole on the pharmacokinetics of itraconazole. Eur. J. Clin. Pharmacol., 1998, 54(2), 159-161.
119. Purkins, L.; Wood, N.; Kleinermans, D.; Nichols, D. Histamine H2-receptor antagonists have no clinically significant effect on the steady-state pharmacokinetics of voriconazole. Br. J. Clin. Pharmacol., 2003, 56, 51-55.
120. Wood, N.; Tan, K.; Purkins, L.; Layton, G.; Hamlin, J.; Kleinermans, D.; Nichols, D. Effect of omeprazole on the steady-state pharmacokinetics of voriconazole. Br. J. Clin. Pharmacol., 2003, 56, 56-61.
121. Saari, T.I.; Laine, K.; Bertilsson, L.; Neuvonen, P.J.; Olkkola, K.T. Voriconazole and fluconazole increase the exposure to oral diazepam. Eur. J. Clin. Pharmacol., 2007, 63(10), 941-949.
122. Krishna, G.; Sansone-Parsons, A.; Kantesaria, B. Drug interaction assessment following concomitant administration of posaconazole and phenytoin in healthy men. Curr. Med. Res. Opin., 2007, 23(6), 1415-1422.
123. Finch, C.K.; Chrisman, C.R.; Baciewicz, A.M.; Self, T.H. Rifampin and rifabutin drug interactions: an update. Arch. Intern. Med., 2002, 162(9), 985-992.
124. Jaruratanasirikul, S.; Kleepkaew, A. Lack of effect of fluconazole on the pharmacokinetics of rifampicin in AIDS patients. J. Antimicrob. Chemother., 1996, 38(5), 877-880.
125. Apseloff, G.; Hilligoss, D.M.; Gardner, M.J.; Henry, E.B.; Inskeep, P.B.; Gerber, N.; Lazar, J.D. Induction of fluconazole metabolism by rifampin: in. vivo study in humans. J. Clin. Pharmacol., 1991, 31(4), 358-361.
126. Nicolau, D.P.; Crowe, H.M.; Nightingale, C.H.; Quintiliani, R. Rifampin-fluconazole interaction in critically ill patients. Ann. Pharmacother, 1995, 29(10), 994-996.
127. Coker, R.J.; Tomlinson, D.R.; Parkin, J.; Harris, J.R.; Pinching, A.J. Interaction between fluconazole and rifampicin. BMJ, 1990, 301(6755), 818.
128. Tseng, A.L.; Walmsley, S.L. Rifabutin-associated uveitis. Ann. Pharmacother., 1995, 29(11), 1149-1155.
129. Becker, K.; Schimkat, M.; Jablonowski, H.; Haussinger, D. Anterior uveitis associated with rifabutin medication in AIDS patients. Infection, 1996, 24(1), 34-36.
130. Jaruratanasirikul, S.; Sriwiriyajan, S. Effect of rifampicin on the pharmacokinetics of itraconazole in normal volunteers and AIDS patients. Eur. J. Clin. Pharmacol., 1998, 54(2), 155-158.
131. Drayton, J.; Dickinson, G.; Rinaldi, M.G. Coadministration of rifampin and itraconazole leads to undetectable levels of serum itraconazole. Clin. Infect. Dis., 1994, 18(2), 266.
132. Todd, J.R.; Arigala, M.R.; Penn, R.L.; King, J.W. Possible clinically significant interaction of itraconazole plus rifampin. Aids Patient Care STDS, 2001, 15(10), 505-510.
133. Ahonen, J.; Olkkola, K.T.; Takala, A.; Neuvonen, P.J. Interaction between fluconazole and midazolam in intensive care patients. Acta Anaesthesiol. Scand., 1999, 43(5), 509-514.
134. Krishna, G.; Moton, A.; Ma, L.; Savant, I.; Martinho, M.; Seiberling, M.; McLeod, J. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers. Clin. Ther., 2009, 31(2), 286-298.
135. Tarumi, Y.; Pereira, J.; Watanabe, S. Methadone and fluconazole: respiratory depression by drug interaction. J. Pain Symp. Manag., 2002, 23(2), 148-153.
136. Cadle, R.M.; Zenon, G.J., III; Rodriguez-Barradas, M.C.; Hamill, R.J. Fluconazole-induced symptomatic phenytoin toxicity. Ann. Pharmacother., 1994, 28(2)., 191-195.
137. Howitt, K.M.; Oziemski, M.A. Phenytoin toxicity induced by fluconazole. Med. J. Aust., 1989, 151(10), 603-604.
138. Mitchell, A.S.; Holland, J.T. Fluconazole and phenytoin: a predictable interaction. BMJ, 1989, 298(6683), 1315.
139. Tucker, R.M.; Denning, D.W.; Hanson, L.H.; Rinaldi, M.G.; Graybill, J.R.; Sharkey, P.K.; Pappagianis, D.; Stevens, D.A. Interaction of azoles with rifampin, phenytoin, and carbamazepine: in. vitro and clinical observations. Clin. Infect. Dis., 1992, 14(1), 165-174.
140. Bonay, M.; Jonville-Bera, A.P.; Diot, P.; Lemarie, E.; Lavandier, M.; Autret, E. Possible interaction between phenobarbital, carbamazepine and itraconazole. Drug Saf., 1993, 9(4), 309-311.
141. Black, D.J.; Kunze, K.L.; Wienkers, L.C.; Gidal, B.E.; Seaton, T.L.; McDonnell, N.D.; Evans, J.S.; Bauwens, J.E.; Trager, W.F. Warfarin-fluconazole II: a metabolically based drug interaction: in. vivo studies. Drug Metab. Dispos., 1996, 24(4), 422-428.
142. Mootha, V.V.; Schluter, M.L.; Das, A. Intraocular hemorrhages due to warfarin fluconazole drug interaction in a patient with presumed Candida endophthalmitis. Arch Ophthalmol., 2002, 120(1), 94-95.
143. Kerr, H.D. Case report: potentiation of warfarin by fluconazole. Am. J. Med. Sci., 1993, 305(3), 164-165.
144. Allison, E.J., Jr.; McKinney, T.J.; Langenberg, J.N. Spinal epidural haematoma as a result of warfarin/fluconazole drug interaction. Eur. J. Emerg. Med., 2002, 9(2), 175-177.
145. Kunze, K.L.; Trager, W.F. Warfarin-fluconazole. III. A rational approach to management of a metabolically based drug interaction. Drug Metab. Dispos., 1996, 24(4), 429-435.
146. Yeh, J.; Soo, S.C.; Summerton, C.; Richardson, C. Potentiation of action of warfarin by itraconazole. BMJ, 1990, 301(6753), 669.
147. Vlahakos, D.V.; Manginas, A.; Chilidou, D.; Zamanika, C.; Alivizatos, P.A. Itraconazole-induced rhabdomyolysis and acute renal failure in a heart transplant recipient treated with simvastatin and cyclosporine. Transplantation, 2002, 73(12)., 1962-1964.
148. Maxa, J.L.; Melton, L.B.; Ogu, C.C.; Sills, M.N.; Limanni, A. Rhabdomyolysis after concomitant use of cyclosporine, simvastatin, gemfibrozil, and itraconazole. Ann. Pharmacother., 2002, 36(5), 820-823.
149. Jalava, K.M.; Partanen, J.; Neuvonen, P.J. Itraconazole decreases renal clearance of digoxin. Ther. Drug Monit., 1997., 19(6), 609-613.
150. Angirasa, A.K.; Koch, A.Z. P-glycoprotein as the mediator of itraconazole-digoxin interaction. J. Am. Podiatr. Med. Assoc., 2002, 92(8), 471-472.
151. Sporanox® (itraconazole) injection [prescribing information]. Raritan, NJ: Ortho Biotech Products, LP; April 2001.
152. Sheehan, D.J.; Hitchcock, C.A.; Sibley, C.M. Current and emerging azole antifungal agents. Clin. Microbiol. Rev., 1999, 12(1), 40-79.
153. Gallagher, J.C.; MacDougall, C.; Dodds Ashley, E.S.; Perfect, J.R. Recent advances in antifungal pharmacotherapy for invasive fungal infections. Exp. Rev. Anti-infective Ther., 2004, 2(2), 253-268.
154. Sabatelli, F.; Patel, R.; Mann, P.A.; Mendrick, C.A.; Norris, C.C.; Hare, R.; Loebenberg, D.; Black, T.A.; McNicholas, P.M. In. vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob. Agents Chemother., 2006, 50(6)., 2009-2015.
155. Herbrecht, R.; Nivoix, Y.; Fohrer, C.; Natarajan-Ame, S.; Letscher- Bru, V. Management of systemic fungal infections: alternatives to itraconazole. J. Antimicrob. Chemother., 2005, 56, i39-i48.
156. Lazarus, H.M.; Blumer, J.L.; Yanovich, S.; Schlamm, H.; Romero, A. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J. Clin. Pharmacol., 2002, 42(4), 395-402.
157. Leveque, D.; Nivoix, Y.; Jehl, F.; Herbrecht, R. Clinical pharmacokinetics of voriconazole. Int. J. Antimicrob. Agents, 2006, 27(4), 274-284.
158. Courtney, R.; Pai, S.; Laughlin, M.; Lim, J.; Batra, V. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob. Agents Chemother., 2003, 47(9), 2788-2795.
159. Krishna, G.; Sansone-Parsons, A. Pharmacokinetics of posaconazole in healthy volunteers: a meta-analysis of five phase 1 studies. Presented at: 41st American Society of Health-System Pharmacists Midyear Clinical Meeting and Exhibition; December 3-7, 2006; Anaheim, Calif.Presented at: 41st ASHP Midyear Clinical Meeting; December 3 - 7, 2006; Anaheim, CA.
160. Kwon, D.S.; Mylonakis, E. Posaconazole: a new broad-spectrum antifungal agent. Exp. Opin. Pharmacother., 2007, 8(8), 1167-1178.
161. Prentice, A.G.; Glasmacher, A. Making sense of itraconazole pharmacokinetics. J. Antimicrob. Chemother., 2005, 56, i17-i22.
162. Barone, J.A.; Moskovitz, B.L.; Guarnieri, J.; Hassell, A.E.; Colaizzi, J.L.; Bierman, R.H.; Jessen, L. Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers. Antimicrob. Agents Chemother., 1998, 42(7), 1862-1865.
163. Boucher, H.W.; Groll, A.H.; Chiou, C.C.; Walsh, T.J. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs, 2004, 64(18), 1997-2020.
164. Kontoyiannis, D.P.; Lionakis, M.S.; Lewis, R.E.; Chamilos, G.; Healy, M.; Perego, C.; Safdar, A.; Kantarjian, H.; Champlin, R.; Walsh, T.J.; Raad, I.I. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J. Infect. Dis., 2005., 191(8), 1350-1360.
165. Siwek, G.T.; Dodgson, K.J.; de Magalhaes-Silverman, M.; Bartelt, L.A.; Kilborn, S.B.; Hoth, P.L.; Diekema, D.J.; Pfaller, M.A. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin. Infect. Dis., 2004, 39(4), 584-587.
166. Imhof, A.; Balajee, S.A.; Fredricks, D.N.; Englund, J.A.; Marr, K.A. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin. Infect. Dis., 2004, 39, 743-746.
167. Groll, A.H.; Walsh, T.J. Posaconazole: clinical pharmacology and potential for management of fungal infections. Exp. Rev. Antiinfect. Ther., 2005, 3(4), 467-487.
168. Cornely, O.A.; Maertens, J.; Winston, D.J.; Perfect, J.; Ullmann, A.J.; Walsh, T.J.; Helfgott, D.; Holowiecki, J.; Stockelberg, D.; Goh, Y.-T.; Petrini, M.; Hardalo, C.; Suresh, R.; Angulo-Gonzalez, D. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med., 2007, 356(4), 348-359.
169. Ullmann, A.J.; Lipton, J.H.; Vesole, D.H.; Chandrasekar, P.; Langston, A.; Tarantolo, S.R.; Greinix, H.; Morais de Azevedo, W.; Reddy, V.; Boparai, N.; Pedicone, L.; Patino, H.; Durrant, S. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med., 2007, 356(4), 335-347.
170. Moton, A.; Ma, L.; Krishna, G.; Malavade, D.; Preston, R.; McLeod, J. The safety, tolerability and pharmacokinetics of the antifungal posaconazole in subjects with hepatic impairment. Poster presented at: 18th European Congress for Clinical Microbiology and Infectious Diseases (ECCMID); April 19-22, 2008; Barcelona, Spain.
171. Dresser, G.K.; Spence, J.D.; Bailey, D.G. Pharmacokineticpharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin. Pharmacokinet., 2000, 38(1), 41-57.
172. Walsh, T.J.; Anaissie, E.J.; Denning, D.W.; Herbrecht, R.; Kontoyiannis, D.P.; Marr, K.A.; Morrison, V.A.; Segal, B.H.; Steinbach, W.J.; Stevens, D.A.; van Burik, J.A.; Wingard, J.R.; Patterson, T.F. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis., 2008, 46(3), 327-360.